{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T01:50:46Z","timestamp":1791942646566,"version":"4.3.4"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T00:00:00Z","timestamp":1616112000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,5,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>The revised vancomycin consensus guidelines recommended area under the curve (AUC)\u2013guided dosing\/monitoring for patients with serious invasive methicillin-resistant Staphylococcus aureus (MRSA) infections as a measure to minimize vancomycin-associated acute kidney injury (VA-AKI) while maintaining similar effectiveness. Data indicate that the intensity of vancomycin exposure drives VA-AKI risk. Troughs of 15\u201320 mg\/L will ensure an AUC \u2265400 mg \u00d7 hr\/L but most patients will have daily AUCs &amp;gt;600. VA-AKI increases as a function of AUC, especially when &amp;gt;600. In addition to minimizing VA-AKI risk while maintaining similar efficacy, AUC-guided dosing\/monitoring is a more precise way to conduct therapeutic drug monitoring for vancomycin relative to trough-only control.<\/jats:p>","DOI":"10.1093\/cid\/ciaa1744","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T20:12:30Z","timestamp":1605298350000},"page":"1497-1501","source":"Crossref","is-referenced-by-count":39,"title":["Vancomycin Area Under the Curve\u2013Guided Dosing and Monitoring for Adult and Pediatric Patients With Suspected or Documented Serious Methicillin-Resistant <i>Staphylococcus aureus<\/i> Infections: Putting the Safety of Our Patients First"],"prefix":"10.1093","volume":"72","author":[{"given":"Thomas P","family":"Lodise","sequence":"first","affiliation":[{"name":"Albany College of Pharmacy and Health Sciences, Albany, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Drusano","sequence":"additional","affiliation":[{"name":"Institute for Therapeutic Innovation, University of Florida, Orlando, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,3,19]]},"reference":[{"key":"2021070813480376700_CIT0001","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am J Health Syst Pharm"},{"key":"2021070813480376700_CIT0002","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1086\/600877","article-title":"Vancomycin therapeutic guidelines: a summary of consensus recommendations from the Infectious Diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists","volume":"49","author":"Rybak","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2021070813480376700_CIT0003","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1093\/clinids\/18.4.544","article-title":"Monitoring serum vancomycin levels: climbing the mountain because it is there?","volume":"18","author":"Moellering","year":"1994","journal-title":"Clin Infect Dis"},{"key":"2021070813480376700_CIT0004","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1177\/2042018816638223","article-title":"Review of vancomycin-induced renal toxicity: an update","volume":"7","author":"Bamgbola","year":"2016","journal-title":"Ther Adv Endocrinol Metab"},{"key":"2021070813480376700_CIT0005","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/phar.2388","article-title":"Vancomycin-induced kidney injury: animal models of toxicodynamics, mechanisms of injury, human translation, and potential strategies for prevention","volume":"40","author":"Pais","year":"2020","journal-title":"Pharmacotherapy"},{"key":"2021070813480376700_CIT0006","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.tiv.2004.03.013","article-title":"Proliferative responses observed following vancomycin treatment in renal proximal tubule epithelial cells","volume":"18","author":"King","year":"2004","journal-title":"Toxicol In Vitro"},{"key":"2021070813480376700_CIT0007","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1128\/AAC.01568-12","article-title":"Systematic review and meta-analysis of vancomycin-induced nephrotoxicity associated with dosing schedules that maintain troughs between 15 and 20 milligrams per liter","volume":"57","author":"van Hal","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480376700_CIT0008","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.2215\/CJN.05920616","article-title":"Vancomycin and the risk of AKI: a systematic review and meta-analysis","volume":"11","author":"Sinha Ray","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2021070813480376700_CIT0009","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1681\/ASN.2008070669","article-title":"Creatinine kinetics and the definition of acute kidney injury","volume":"20","author":"Waikar","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2021070813480376700_CIT0010","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/cc11426","article-title":"Acute kidney injury and residual renal function","volume":"16","author":"Ronco","year":"2012","journal-title":"Crit Care"},{"key":"2021070813480376700_CIT0011","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1186\/s13054-016-1353-y","article-title":"Acute kidney injury: short-term and long-term effects","volume":"20","author":"Doyle","year":"2016","journal-title":"Crit Care"},{"key":"2021070813480376700_CIT0012","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.clinthera.2007.06.014","article-title":"A retrospective analysis of possible renal toxicity associated with vancomycin in patients with health care-associated methicillin-resistant Staphylococcus aureus pneumonia","volume":"29","author":"Jeffres","year":"2007","journal-title":"Clin Ther"},{"key":"2021070813480376700_CIT0013","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.clinthera.2011.12.013","article-title":"Incidence of nephrotoxicity and association with vancomycin use in intensive care unit patients with pneumonia: retrospective analysis of the IMPACT-HAP database","volume":"34","author":"Cano","year":"2012","journal-title":"Clin Ther"},{"key":"2021070813480376700_CIT0014","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/cir124","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021070813480376700_CIT0015","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1128\/AAC.00173-11","article-title":"Applying new diagnostic criteria for acute kidney injury to facilitate early identification of nephrotoxicity in vancomycin-treated patients","volume":"55","author":"Minejima","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480376700_CIT0016","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40261-018-0686-5","article-title":"Potential for cost saving with iclaprim owing to avoidance of vancomycin-associated acute kidney injury in hospitalized patients with acute bacterial skin and skin structure infections","volume":"38","author":"Patel","year":"2018","journal-title":"Clin Drug Investig"},{"key":"2021070813480376700_CIT0017","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01268-20","article-title":"Effect of vancomycin-associated acute kidney injury on incidence of 30-day readmissions among hospitalized veterans\u2019 affairs patients with skin and skin structure infections","author":"Patel","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480376700_CIT0018","doi-asserted-by":"crossref","first-page":"2725","DOI":"10.1093\/jac\/dkaa184","article-title":"Relationship of vancomycin trough levels with acute kidney injury risk: an exposure\u2013toxicity meta-analysis","volume":"75","author":"Bellos","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"2021070813480376700_CIT0019","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/cir895","article-title":"Linezolid in methicillin-resistant Staphylococcus aureus nosocomial pneumonia: a randomized, controlled study","volume":"54","author":"Wunderink","year":"2012","journal-title":"Clin Infect Dis"},{"key":"2021070813480376700_CIT0020","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/phar.1638","article-title":"Vancomycin trough concentration as a predictor of clinical outcomes in patients with staphylococcus aureus bacteremia: a meta-analysis of observational studies","volume":"35","author":"Prybylski","year":"2015","journal-title":"Pharmacotherapy"},{"key":"2021070813480376700_CIT0021","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1093\/cid\/cir078","article-title":"Vancomycin: we can\u2019t get there from here","volume":"52","author":"Patel","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2021070813480376700_CIT0022","article-title":"Vancomycin dose recommendations for hospital-, ventilator- or health care-associated pneumonia and the attainment of vancomycin trough concentrations of 15\u201320 mg\/l: cognitive dissonance.","author":"Drusano","year":"2007"},{"key":"2021070813480376700_CIT0023","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1093\/cid\/ciz460","article-title":"The emperor\u2019s new clothes: prospective observational evaluation of the association between initial vancomycin exposure and failure rates among adult hospitalized patients with methicillin-resistant staphylococcus aureus bloodstream infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2021070813480376700_CIT0024","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1093\/cid\/ciz051","article-title":"Vancomycin area under the curve and acute kidney injury: a meta-analysis","volume":"69","author":"Aljefri","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021070813480376700_CIT0025","article-title":"Prospective trial on the use of trough concentration versus area under the curve to determine therapeutic vancomycin dosing","volume":"62:e02042\u201317","author":"Neely","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2021070813480376700_CIT0026","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"2021070813480376700_CIT0027","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1309\/AJCPDSYS0DVLKFOH","article-title":"What proportion of vancomycin trough levels are drawn too early? Frequency and impact on clinical actions","volume":"137","author":"Morrison","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"2021070813480376700_CIT0028","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1023\/B:JOPA.0000029490.76908.0c","article-title":"A Bayesian approach to tracking patients having changing pharmacokinetic parameters","volume":"31","author":"Bayard","year":"2004","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"2021070813480376700_CIT0029","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01293-17","article-title":"A quasi-experiment to study the impact of vancomycin area under the concentration-time curve-guided dosing on vancomycin-associated nephrotoxicity","author":"Finch","year":"2017","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciaa1744\/36645947\/ciaa1744.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/9\/1497\/37795851\/ciaa1744.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/72\/9\/1497\/37795851\/ciaa1744.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,8]],"date-time":"2021-07-08T22:31:00Z","timestamp":1625783460000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/72\/9\/1497\/6178884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,19]]},"references-count":29,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2021,3,19]]},"published-print":{"date-parts":[[2021,5,4]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciaa1744","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,3,19]]}}}